|
Feb 24
|
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
|
|
Feb 23
|
CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now
|
|
Feb 20
|
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Feb 18
|
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
|
|
Feb 16
|
Street Calls of the Week
|
|
Feb 15
|
Why CRISPR Therapeutics (CRSP) Soared on Friday?
|
|
Feb 14
|
CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99
|
|
Feb 14
|
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
|
|
Feb 12
|
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
|
|
Feb 12
|
Crispr Therapeutics price target raised to $86 from $85 at BofA
|
|
Feb 12
|
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
|
|
Feb 11
|
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 11
|
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 10
|
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
|
|
Dec 30
|
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In?
|
|
Dec 29
|
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
|
|
Sep 25
|
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
|
|
Sep 5
|
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
|
|
Sep 4
|
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
|